David CHARDIN

Dr. David CHARDIN

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
OHO. Humbert
O. Humbert
NCN. Cadour
N. Cadour
MPM. Paquet
M. Paquet
RSR. Schiappa
R. Schiappa
MPM. Poudenx
M. Poudenx
JOJ. Otto
J. Otto

23 July 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
DCDavid CHARDIN
David CHARDIN
MPMarie Paquet
Marie Paquet
RSRenaud Schiappa
Renaud Schiappa
JDJacques Darcourt
Jacques Darcourt
CBCaroline Bailleux
Caroline Bailleux
OHOlivier Humbert
Olivier Humbert
Background: Reliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic and predictive values of different baseline metabolic parameters, including metabolic tumor volume (MTV), from 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT) scans in patients with NSCLC treated with PD1 inhibitors. Methods: Maximum and peak standardized uptake values, MTV and total lesion glycolysis (TLG), as well as clinical and biological parameters, were recorded in 75 prospectively included patients with NSCLC treated with PD1 inhibitors. Associations between these parameters and overall survival (OS) were evaluated as well as their accuracy to predict early treatment discontinuation (ETD). Results: A high MTV and a high TLG were significantly associated with a lower OS (p<0.001). The median OS in patients with MTV above the median (36.5 cm3) was 10.5 months (95% CI: 6.2 to upper limit: unreached), while the median OS in patients with MTV below the median was not reached. Patients with no prior chemotherapy had a poorer OS than patients who had received prior systemic treatment (p=0.04). MTV and TLG could reliably predict ETD (area under the receiver operating characteristic curve=0.76, 95% CI: 0.65 to 0.87 and 0.72, 95% CI: 0.62 to 0.84, respectively). Conclusion: MTV is a strong prognostic and predictive factor in patients with NSCLC treated with PD1 inhibitors and can be easily determined from routine 18F-FDG PET/CT scans. MTV, could help to personalize immunotherapy and be used to stratify patients in future clinical studies.

5 January 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
OHOlivier Humbert
Olivier Humbert
VBVéronique Bourg
Véronique Bourg
LMLydiane Mondot
Lydiane Mondot
JGJocelyn Gal
Jocelyn Gal
PBPierre-Yves Bondiau
Pierre-Yves Bondiau
JDJacques Darcourt
Jacques Darcourt

1 June 2017 in Medicine
Verified
Journal Article
Open access
PDF file
DCDavid CHARDIN
David CHARDIN
GNGuillaume Nivaggioni
Guillaume Nivaggioni
PVPhilippe Viau
Philippe Viau
CBCaherine Butori
Caherine Butori
BPBernard Padovani
Bernard Padovani
MRMicheline Razzouk-Cadet
Micheline Razzouk-Cadet
Exogenous lipoid pneumonia is a rare condition due to abnormal presence of oily substances in the lungs. It is a rarely known cause for false positive 18FDG PET-CT results and can sometimes lead to invasive investigations. Searching and finding the source of the oily substance is one of the keys to the diagnosis. Inhalation of oily drugs during snorting has rarely been described. A patient with well controlled HIV infection was referred for an 18FDG PET-CT to assess extension of Kaposi's disease, recently removed from his right foot. The patient had no particular symptoms. Abnormal uptake of 18FDG was found in a suspicious lung nodule. An experienced radiologist thought the nodule was due to lipoid pneumonia. Bronchoalveolar lavage fluid did not contain lipid-laden macrophages but bronchoscopy showed violet lesions resembling Kaposi's disease lesions. Lobectomy was performed after a multidisciplinary discussion. Anatomopathological analysis revealed the nodule was due to lipoid pneumonia. The patient's quality of life did not diminish after the operation and he is still in good health. The source of the oily substance causing lipoid pneumonia was found after the surgery: the patient used to snort oily drugs. The presence of a suspicious lung nodule possibly due to lipoid pneumonia in a patient with known Kaposi's disease was difficult to untangle and lead to invasive surgery. It is possible that if a source of exogenous lipoid pneumonia had been found beforehand, surgery could have been prevented.

Verified
Journal Article
Open access
PDF file
DCDavid CHARDIN
David CHARDIN
LJLun JING
Lun JING
MCMélanie Chazal-Ngo-Mai
Mélanie Chazal-Ngo-Mai
JGJean-Marie Guigonis
Jean-Marie Guigonis
VRValerie Rigau
Valerie Rigau
FBFanny BUREL-VANDENBOS
Fanny BUREL-VANDENBOS
The aim of this study was to identify metabolomic signatures associated with the gliomagenesis pathway (IDH-mutant or IDH-wt) and tumor grade of diffuse gliomas (DGs) according to the 2021 WHO classification on frozen samples and to evaluate the diagnostic performances of these signatures in tumor samples that are formalin-fixed and paraffin-embedded (FFPE). An untargeted metabolomic study was performed using liquid chromatography/mass spectrometry on a cohort of 213 DG samples. Logistic regression with LASSO penalization was used on the frozen samples to build classification models in order to identify IDH-mutant vs. IDH-wildtype DG and high-grade vs low-grade DG samples. 2-Hydroxyglutarate (2HG) was a metabolite of interest to predict IDH mutational status and aminoadipic acid (AAA) and guanidinoacetic acid (GAA) were significantly associated with grade. The diagnostic performances of the models were 82.6% AUC, 70.6% sensitivity and 80.4% specificity for 2HG to predict IDH status and 84.7% AUC, 78.1% sensitivity and 73.4% specificity for AAA and GAA to predict grade from FFPE samples. Thus, this study showed that AAA and GAA are two novel metabolites of interest in DG and that metabolomic data can be useful in the classification of DG, both in frozen and FFPE samples.

23 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CBCaroline BAILLEUX
Caroline BAILLEUX
DCDavid CHARDIN
David CHARDIN
JGJocelyn Gal
Jocelyn Gal
JGJean-Marie Guigonis
Jean-Marie Guigonis
SLSabine Lindenthal
Sabine Lindenthal
TPThierry Pourcher
Thierry Pourcher
Purpose: Identification of metabolomic biomarkers of high SBR grade in non-metastatic breast cancer. Methods: This retrospective bicentric metabolomic analysis included a training set (n = 51) and a validation set (n = 49) of breast cancer tumors, all classified as high-grade (grade III) or low-grade (grade I–II). Metabolomes of tissue samples were studied by liquid chromatography coupled with mass spectrometry. Results: A molecular signature of the top 12 metabolites was identified from a database of 602 frequently predicted metabolites. Partial least squares discriminant analyses showed that accuracies were 0.81 and 0.82, the R2 scores were 0.57 and 0.55, and the Q2 scores were 0.44431 and 0.40147 for the training set and validation set, respectively; areas under the curve for the Receiver Operating Characteristic Curve were 0.882 and 0.886. The most relevant metabolite was diacetylspermine. Metabolite set enrichment analyses and metabolic pathway analyses highlighted the tryptophan metabolism pathway, but the concentration of individual metabolites varied between tumor samples. Conclusions: This study indicates that high-grade invasive tumors are related to diacetylspermine and tryptophan metabolism, both involved in the inhibition of the immune response. Targeting these pathways could restore anti-tumor immunity and have a synergistic effect with immunotherapy. Recent studies could not demonstrate the effectiveness of this strategy, but the use of theragnostic metabolomic signatures should allow better selection of patients.